A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
for Metastatic Castration-resistant Prostate Cancer (mCRPC)
57 locations incl. Tucson
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06136650·Phase 3·Recruiting·Listed Nov 2023